Soligenix, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SNGX Nasdaq 2830 www.soligenix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Soligenix, Inc.

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine - Jun 8th, 2026 5:30 am
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy - May 27th, 2026 5:28 am
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo - May 26th, 2026 5:30 am
SNGX: Continuing to Analyze FLASH2 Data - May 14th, 2026 8:08 am
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - May 8th, 2026 5:30 am
SNGX: FLASH2 Trial Recommended to Stop for Futility - Apr 29th, 2026 7:13 am
SNGX Phase 3 Trial Halted on HyBryte - Apr 28th, 2026 9:06 am
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma - Apr 28th, 2026 5:30 am
Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - Apr 21st, 2026 1:00 pm
Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - Apr 20th, 2026 12:23 pm
Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results - Apr 17th, 2026 12:30 pm
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Apr 10th, 2026 8:00 am
SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26 - Apr 6th, 2026 9:45 am
Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - Apr 2nd, 2026 1:30 pm
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - Apr 2nd, 2026 5:30 am
Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - Apr 1st, 2026 1:00 pm
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - Mar 31st, 2026 5:30 am
Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet Disease - Mar 26th, 2026 1:30 pm
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease - Mar 26th, 2026 5:30 am
Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - Mar 25th, 2026 12:45 pm